drug

REC-7735

1 story · latest Sep 14, 2026

Status: Investigational
Trials: 1 registered trial in coverage

Relationships

Developed by Recursion Pharmaceuticals, Inc.

Timeline

Recursion registers Phase 1/2 trial of REC-7735 in PIK3CA-H1047R solid tumors

Sep 14Trial updateREC-7735 Recursion Pharmaceuticals, Inc.

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.